Back to Search
Start Over
Higher prescription of antidepressants and/or anxiolytics among chronic obstructive pulmonary disease patients
- Source :
- Therapeutic Advances in Respiratory Disease, Vol 15 (2021), Therapeutic Advances in Respiratory Disease, Therapeutic Advances in Respiratory Disease, 15, 1. SAGE Publications Ltd, Therapeutic advances in respiratory disease, 15. SAGE Publications Ltd
- Publication Year :
- 2021
- Publisher :
- SAGE Publishing, 2021.
-
Abstract
- Background: Chronic obstructive pulmonary disease (COPD) is often accompanied by psychiatric problems, such as depression and anxiety, affecting both treatment outcomes and mortality. Evidence for the number of COPD patients using medication for these disorders is sparse. In this study, chronic antidepressant (ATD) and anxiolytic (ANX) drug use – to identify depression and anxiety – among COPD patients was compared with subjects with or without other chronic diseases. Methods: The NControl database containing prescription data of 800 pharmacies including 7 million individuals in The Netherlands was used. Patients of age 55+ years who received frequent prescriptions – at least two/year in 5 out of 6 years – for COPD medication, dermatological drugs, disease-modifying antirheumatic drugs (DMARDs), statins and oral glucose-lowering medication were analyzed for concomitant chronic use of ATDs and ANXs between 1 January 2013 and 1 January 2019. All other subjects aged 55+ years were included as a control group (control group 1). This group was further stratified into a group of subjects that received frequent prescriptions of any kind (control group 2). Results: 15.2% of the patients that receive COPD treatment ( n = 96,319), 15.3% of subjects that are treated for dermatological problems ( n = 62,865), 13.2% of subjects that receive DMARDs ( n = 7900), 11.6% of statins users ( n = 422,376) and 11.4% of oral glucose-lowering medication users ( n = 165,975) are also chronically treated for depression or anxiety, compared with 2.6% (control group 1; n = 3,290,608) and 11.4% (control group 2; n = 757,947). In general, female and 75+ years aged subjects showed a higher risk for using ATDs and ANXs chronically. In the COPD and the dermatological patient group the risk was the highest compared with the other patient groups. Conclusions: The rates of chronic ATD and ANX use and the risk of having depression and/or anxiety are especially high in COPD patients, indicating that psychiatric problems are more common in COPD than in most other chronic diseases. In general, age and gender strongly influence the risk of chronically using ATDs and ANXs. The reviews of this paper are available via the supplemental material section.
- Subjects :
- Pulmonary and Respiratory Medicine
Male
medicine.medical_specialty
Databases, Factual
Treatment outcome
Pulmonary disease
Anxiety
antidepressive agents
Cohort Studies
03 medical and health sciences
Pulmonary Disease, Chronic Obstructive
0302 clinical medicine
Sex Factors
Anti-Anxiety Agents
Risk Factors
Internal medicine
medicine
Humans
Pharmacology (medical)
030212 general & internal medicine
Medical prescription
Depression (differential diagnoses)
Original Research
pulmonary disease
Aged
Netherlands
Retrospective Studies
lcsh:RC705-779
COPD
chronic obstructive
business.industry
Depression
Age Factors
lcsh:Diseases of the respiratory system
Middle Aged
medicine.disease
Antidepressive Agents
Chronic disease
030228 respiratory system
prescriptions
Female
medicine.symptom
anti-anxiety agents
business
chronic disease
Subjects
Details
- Language :
- English
- ISSN :
- 17534666 and 17534658
- Volume :
- 15
- Database :
- OpenAIRE
- Journal :
- Therapeutic Advances in Respiratory Disease
- Accession number :
- edsair.doi.dedup.....8a08618e00a1d72149a5f84494313b77